Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Non-Current Deferred Tax Liability (2016 - 2022)

ImmunityBio (IBRX) has disclosed Non-Current Deferred Tax Liability for 7 consecutive years, with $162000.0 as the latest value for Q2 2022.

  • On a quarterly basis, Non-Current Deferred Tax Liability fell 4.71% to $162000.0 in Q2 2022 year-over-year; TTM through Jun 2022 was $162000.0, a 4.71% decrease, with the full-year FY2021 number at $162000.0, down 4.71% from a year prior.
  • Non-Current Deferred Tax Liability was $162000.0 for Q2 2022 at ImmunityBio, roughly flat from $162000.0 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $374000.0 in Q1 2018 to a low of $122000.0 in Q3 2018.
  • A 4-year average of $191200.0 and a median of $170000.0 in 2020 define the central range for Non-Current Deferred Tax Liability.
  • Peak YoY movement for Non-Current Deferred Tax Liability: crashed 82.09% in 2018, then dropped 4.71% in 2021.
  • ImmunityBio's Non-Current Deferred Tax Liability stood at $122000.0 in 2018, then soared by 39.34% to $170000.0 in 2020, then decreased by 4.71% to $162000.0 in 2021, then changed by 0.0% to $162000.0 in 2022.
  • Per Business Quant, the three most recent readings for IBRX's Non-Current Deferred Tax Liability are $162000.0 (Q2 2022), $162000.0 (Q1 2022), and $162000.0 (Q4 2021).